Navigation Links
Labopharm Reports Results for First Quarter Fiscal 2008
Date:5/8/2008

- Once-Daily Tramadol Continues to Gain Market Share in Europe and Canada;

Company Preparing NDA for Trazodone Contramid(R) Once-a-Day -

LAVAL, QC, May 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its results for the first quarter ended March 31, 2008. All figures are in Canadian dollars unless otherwise stated.

"While we continue to make strong progress in the global commercialization of our once-daily tramadol product, we are preparing the New Drug Application for our second product, trazodone Contramid(R) once-a-day, for submission prior to year-end, and have initiated the Phase III clinical study for our third product, a twice-daily formulation of tramadol and acetaminophen," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "In our global commercialization program for once-daily tramadol, our product has been launched in 10 countries, including Poland earlier this year, and is steadily gaining market(1) share in Europe(2) and Canada. In February, the latest month for which data is available, our product was the best selling once-daily tramadol product in four of the five largest European markets."

Mr. Howard-Tripp added, "We are encouraged by the positive Phase III results for trazodone Contramid(R) once-a-day. One of the greatest challenges in treating depression is that up to 50% of patients discontinue their medication within six months of initiating treatment and, therefore would benefit from an alternative treatment option. Patients need rapid improvement of their depressive symptoms and may experience insomnia and agitation. Our study demonstrated that trazodone Contramid(R) once-a-day was statistically superior to placebo by the end of the first week of treatment and was associated with an improvement in overall sleep quality. Accordingly, we are optimistic about the prospects for our formulation in the market for antidepressants."

Financial Summ
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... treatment and variations in the quality of care are ... patients still varies widely between regions within Europe, according ... adults to date, published in The Lancet Oncology ... for most cancers of the blood has increased over ... of new targeted drugs in the early 2000s such ...
(Date:7/13/2014)... test for diagnosing type-1 diabetes could improve patient ... disease, according to the device,s inventors at the ... a paper to be published online July 13 ... nanotechnology to detect type-1 diabetes outside hospital settings. ... forms of diabetes mellitus, which are both characterized ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for ... wells as to maintain soil quality. The application of ... a dominant revenue generator for manufacturers in future. The ... costs has led to the adoption of micro irrigation ... caused massive demand for micro irrigation systems, as they ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... The federal court overseeing thousands of ... against Johnson & Johnson’s Ethicon, Inc. is preparing to ... to get underway next month. According to an Amended ... Southern District of West Virginia on July 9, 2014, ... 2014 at 3:00 p.m. July selection is slated to ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... a Japanese study have given drug giant Novartis AG, ... The Lancet, the company’s blood pressure// drug Diovan was observed ... up to 40 percent. , The study titled the ... to 79, with high blood pressure, ischemic heart disease or ...
... from MetroHealth Medical Center and Case Western Reserve University ... have had previous spontaneous preterm births with 17 Alpha ... preterm birth would consequently reduce both short-term and lifetime ... The results of their study are reported in the ...
... study has showed that a particular group of its citizens; ... lion’s share of the arthritis// population, as well as its ... study, Edward Yelin, professor of medicine and health at the ... those with arthritis and other rheumatic conditions have increased to ...
... medication errors, says a new study by University of Arizona ... the journal Medical Care. ,The study was conducted ... professor Daniel C. Malone, Ph.D., who is also a member ... at the Critical Path Institute. ,Researchers reviewed data ...
... associated with depression in women, according to researchers at ... study being published in a recent issue of Preventive ... and depression in women. In addition, self-weighing daily, rather ... lower Body Mass Index (BMI) levels in women 40 ...
... Jose Gomes Temporao on Wednesday signed a decree declaring that ... generic version of Merck's// antiretroviral Efavirenz if the company does ... ,According to the decree, Efavirenz is a "public interest" ... not issue the decree "as a threat, nor to lower ...
Cached Medicine News:Health News:Novartis Drug Diovan Shows Superior Benefits 2Health News:Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs 2Health News:America’s Arthritis Patients Take Sizeable Chunks Of Healthcare Econom 2Health News:Pharmacists' Workload Contributes To Errors 2Health News:Brazil Will Purchase Merck’s Antiretroviral If Price Not Lowere 2
(Date:7/13/2014)... 2014  Eli Lilly and Company (NYSE: ... non-clinical study in genetically engineered mice examining combination ... antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data ... in removing clumps of amyloid-beta protein in the ... lead to Alzheimer,s disease (AD) – than use ...
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... chronic idiopathic,thrombocytopenic purpura increased and maintained platelet ... with extended treatment, ATLANTA, Dec. 10 ... safety and efficacy of its investigational,drug PROMACTA(TM) ... purpura (ITP).(1) These preliminary results from the,EXTEND ...
... trial specifically designed to evaluate erectile ... function in ED patients with dyslipidemia, ... specifically designed to evaluate erectile function in,erectile dysfunction (ED) ... treating ED, significantly improves the ability,of men with ED ...
Cached Medicine Technology:Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting 2Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting 3Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting 4New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol 2New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol 3New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol 4New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: